Dr. James Janopaul-Naylor is a radiation oncologist specializing in the treatment of prostate cancer, bladder cancer, brain cancers, intensity-modulated radiation therapy, and stereotactic body radiation therapy at the Memorial Sloan Kettering Cancer Center. He completed his MD from the Perelman School of Medicine at the University of Pennsylvania and residencies for Radiation Oncology at Emory University. He received the Housestaff Professionalism Award from Emory University School of Medicine (2020), the Resident Service and Mentoring Award from Winship Cancer Institute (2021), the Early Career Oncologist Award from American Radium Society Inc. (2021), and the Conquer Cancer Merit Award from American Society of Clinical Oncology (2022).
Dr. Brandon A. Mahal is a physician-scientist at the University of Miami Miller School of Medicine (MSOM)-Sylvester Comprehensive Cancer Center (SCCC). Dr. Mahal obtained his Doctor of Medicine (M.D.) with Honors at Harvard Medical School, completed an internal medicine internship at Harvard Medical School’s Brigham and Women’s Hospital, and completed a residency in radiation oncology at the Harvard Radiation Oncology Program. He is an internationally recognized expert in prostate cancer and health equity, with over 200 co-authored manuscripts, including several publications in top medical journals such as NEJM, JAMA, and JAMA Oncology. Dr. Mahal has served on several expert committees and panels, including The White House’s Health Equity Leader Roundtable, The Lancet Commission on Prostate Cancer, The American Society for Clinical Oncology (ASCO) Guideline Panel on Genomics for Prostate Cancer, American Cancer Society (ACS) National Advisory Team on Prostate Cancer Disparities, and Prostate Cancer Foundation Disparities Working Group. He also leads a research lab that focuses on prostate cancer, translational epidemiology, genomics, and scientific outreach/engagement in the context of addressing cancer disparities. His work is funded by the Prostate Cancer Foundation (PCF), American Society for Radiation Oncology (ASTRO), Department of Defense (DOD), National Institutes of Health (NIH), and generous donations through the Sylvester Comprehensive Cancer Center (SCCC).
Dr. Kosj Yamoah is Chair in the Department of Radiation Oncology with a secondary appointment in the Cancer Epidemiology Program at Moffitt Cancer Center. Dr. Yamoah’s clinical focus is genitourinary malignancies. He currently serves as the Section Head for Genitourinary Radiation Oncology and Director for Radiation Oncology Health Disparities Research. He is committed to increasing access and quality of care among the minority population, particularly men of African descent. His clinical expertise focuses on prostate cancer, prostate brachytherapy, intensity-modulation radiation therapy (IMRT), and image-guided radiation therapy (IGRT). Dr. Yamoah received his MD degree from the Icahn School of Medicine at Mount Sinai in New York and his PhD in Oncological Science from Mount Sinai Graduate School of Biological Sciences and Memorial Sloan Kettering Cancer Center, also in New York, NY. Dr. Yamoah completed a radiation oncology residency at Thomas Jefferson University in Philadelphia, PA, where he served as chief resident. He also completed a research fellowship in prostate cancer disparities and epidemiology at the University of Pennsylvania. He is currently funded by the Department of Defense, American Cancer Society, Prostate Cancer Foundation, and the National Institute of Health. He is also the lead principal investigator for the Department of Veterans Affairs PCF award to develop Precision Oncology Centers of Excellence within the Bay Pines and James Haley VAs.
Dr. Sean McBride is the Chief of External Beam Radiotherapy Manhattan at the Memorial Sloan Kettering Cancer Center. He is also a board-certified radiation oncologist with expertise in treating primary genitourinary (prostate, bladder, kidney, and testicular) and head and neck (oral cavity, base of tongue, tonsil, larynx, hypopharynx, sinus, nasopharynx, and thyroid) malignancies. He earned his BS in Molecular Biophysics & Biochemistry in 2003 and his MD from Yale University School of Medicine in 2008. He completed his residency at the Brigham and Women’s Hospital (Radiation Oncology) during 2009–2013. At Memorial Sloan Kettering Cancer Center, he works with a dedicated team of medical oncologists, surgeons, and medical physicists to help deliver individualized care using sophisticated radiation therapy techniques, including image-guided, stereotactic radiosurgery (IGRT), intensity-modulated radiation therapy (IMRT), and brachytherapy.
Dr. Paul L. Nguyen is an internationally recognized expert in prostate cancer clinical care and research. He has published over 350 original research articles and has national leadership as Co-Chair of the National Cancer Institute's GU Steering Committee, Chair of the ARS/ACR Appropriateness Criteria Committee for Prostate Cancer, and Chair of the ASTRO Annual Refresher Course. He is the principal investigator of the multi-center randomized FORMULA-509 trial and the national NRG Oncology GU-009/PREDICT-RT trial and co-chair of the international randomized ENZARAD trial. His research is supported by an NIH R-01 grant. He serves as the DF/BWCC Genitourinary Clinical Center Director for Radiation Oncology, Vice-Chair for Clinical Research in the Department of Radiation Oncology, Professor at Harvard Medical School, and Baldwin-Politi Distinguished Chair in Oncology at Brigham and Women's Hospital, where he is also associate director of the Harvard Radiation Oncology Program residency. He received his AB from Harvard College, MD from Harvard Medical School, MBA from the MIT Sloan School of Management, and completed his residency at the Harvard Radiation Oncology Program, where he served as chief resident.
Prof. Neha Vapiwala is a professor and vice chair of education in the Department of Radiation Oncology at the University of Pennsylvania. She specializes in the management of patients with genitourinary (GU) cancers. She earned her MD from the University of Pennsylvania in 2001. Her work focuses on biological and technological improvements in the delivery of photon- and proton-based radiation, and she currently serves as the principal investigator of multiple therapeutic trials for prostate cancer patients, including a recently activated national phase III randomized clinical trial on the use of PET scan findings to direct local and systemic treatment intensification in patients with post-prostatectomy biochemical recurrence through the ECOG-ACRIN cooperative group. She is a member of numerous national and international scientific committees dedicated to GU cancer research and education, including the American Society of Clinical Oncology (ASCO) and American Society of Radiation Oncology (ASTRO) Scientific Program Committees and the National Cancer Institute's Prostate Cancer Task Force. She previously served as Assistant Dean of Student Affairs and was named the Associate Dean of Admissions at the University of Pennsylvania’s Perelman School of Medicine in 2019. She is also the current chair of the Accreditation Council for Graduate Medical Education's Residency Review Committee for Radiation Oncology, which oversees national training standards for her specialty.
